| 刘满庆,黄剑.肺癌组织不同核因子E2相关因子2及切除修复交叉互补基因1水平在接受含铂化疗方案的晚期非小细胞肺癌患者预后中的价值[J].安徽医药,2018,22(12):2369-2372. |
| 肺癌组织不同核因子E2相关因子2及切除修复交叉互补基因1水平在接受含铂化疗方案的晚期非小细胞肺癌患者预后中的价值 |
| Prognostic value of different Nrf2 and ERCC1 levels in advanced NSCLC patients receiving platinum chemotherapy regimen |
| 投稿时间：2017-06-16 |
| DOI： |
| 中文关键词: 非小细胞肺癌 核因子E2相关因子2 切除修复交叉互补基因1 含铂化疗 预后 |
| 英文关键词: NSCLC Nrf2 ERCC1 Platinum chemotherapy regimen Prognosis |
| 基金项目: |
|
| 摘要点击次数: 1904 |
| 全文下载次数: 637 |
| 中文摘要: |
| 目的 分析肺癌组织不同核因子E2相关因子2(Nrf2)及切除修复交叉互补基因1(ERCC1)水平在接受含铂化疗方案的晚期非小细胞肺癌(NSCLC)患者预后中的价值。 方法 以淮安市第一人民医院2010年1月至2012年12月期间收治的130例晚期NSCLC患者为研究对象,所有患者均接受含铂化疗方案,分析Nrf2及ERCC1表达水平对患者生存期的影响。 结果 肺癌组织的Nrf2阳性率、ERCC1阳性率分别高于癌旁组织的Nrf2阳性率、ERCC1阳性率(P＜0.05)。有胸腔积液的患者Nrf2阳性率高于无胸腔积液患者,TNM分期为Ⅳ期的患者Nrf2阳性率高于Ⅲ期患者,转移病灶数≥2个、原发肿瘤直径≥5 cm和有淋巴结转移的患者的Nrf2阳性率、ERCC1阳性率均高于对立条件下Nrf2阳性率、ERCC1阳性率(均P＜0.05)。ERCC1阳性患者和Nrf2阳性患者的中位生存时间均短于阴性患者的中位生存时间(均P＜0.05)。转移病灶数、淋巴结转移、ERCC1表达和Nrf2表达是影响晚期NSCLC患者生存期的危险因素。 结论 ERCC1表达和Nrf2表达水平可作为晚期NSCLC患者进行含铂化疗方案在预后方面的参考性预测因素。 |
| 英文摘要: |
| Objective To analyse prognostic value of different nuclear factor E2-related factor 2 (Nrf2) and excision repair cross complementing gene 1 (ERCC1) levels in lung cancer patients with advanced non-small cell lung cancer (NSCLC) receiving platinum chemotherapy regimen. Methods 130 patients with advanced NSCLC from January 2010 to December 2012 receiving platinum chemotherapy regimen were analyzed by the expression levels of Nrf2 and ERCC1 in the survival of patients. Results The positive rate of Nrf2 and positive rate of ERCC1 in lung cancer tissue were higher than that of paracancerous tissue (P＜0.05).The positive rate of Nrf2 in patients with pleural effusion was higher than that of patients without pleural effusion.The positive rate of Nrf2 and ERCC1 in patients with stage Ⅳ or metastatic lesions greater than 2 or diameter of the primary tumor was greater than 5 cm,lymph node metastasis was higher than that of opposite condition (all P＜0.05).Median survival time in ERCC1 positive patients and Nrf2 positive patients were shorter than that of negative patients (all P＜0.05).Number of metastatic lesions,lymph node metastasis,expression level of ERCC1 and Nrf2 are independent risk factor for the survival of advanced NSCLC patients. Conclusion Level of ERCC1 and Nrf2 can be used as a reference predictor of prognosis in advanced NSCLC patients with platinum chemotherapy regimen. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
